SCHEMBL3283

SCHEMBL3283

CCOC(=O)C1CCC(N)CC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
SMYD3 Q9H7B4 1/20 0.49
ALDH1A1 P00352 3/20 0.49
PPM1B O75688 1/20 0.49
PTPN1 P18031 1/20 0.49
PPP1CC P36873 1/20 0.49
HSD11B1 P28845 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
LGMN Q99538 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL826452 1.00 MAPT (0.51) MAPTSMYD3ALDH1A1PPM1BPTPN1
SCHEMBL852813 1.00 MAPT (0.51) MAPTSMYD3ALDH1A1PPM1BPTPN1
Hydrochloric Acid SCHEMBL385320 0.98 MAPT (0.50) MAPTSMYD3ALDH1A1PPM1BPTPN1
Hydrochloric Acid SCHEMBL4714966 0.98 MAPT (0.50) MAPTSMYD3ALDH1A1PPM1BPTPN1
Hydrochloric Acid SCHEMBL4714961 0.98 MAPT (0.50) MAPTSMYD3ALDH1A1PPM1BPTPN1
Hydrochloric Acid SCHEMBL853961 0.98 MAPT (0.50) MAPTSMYD3ALDH1A1PPM1BPTPN1
Hydrochloric Acid SCHEMBL3195558 0.98 MAPT (0.50) MAPTSMYD3ALDH1A1PPM1BPTPN1
SCHEMBL8891623 0.89 MAPT (0.60) MAPTALDH1A1PPM1BPTPN1PPP1CC
SCHEMBL2375356 0.89 MAPT (0.60) MAPTALDH1A1PPM1BPTPN1PPP1CC
SCHEMBL4221 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283009-B1 INHIBITORS OF JNK HOFFMANN LA ROCHE (CH) 2012-08-29 EP claimed
US-8183254-B2 Inhibitors of JNK ROCHE PALO ALTO LLC (US) 2012-05-22 US claimed
EP-2283009-A1 INHIBITORS OF JNK F. Hoffmann-La Roche AG (CH) 2011-02-16 EP claimed
US-20090318484-A1 Inhibitors of JNK ROCHE PALO ALTO LLC 2009-12-24 US claimed
WO-2009138340-A1 INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2009-11-19 WO claimed
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
US-12459931-B2 Benzothiophene derivative regulator, preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-11-04 US disclosed
CN-119431323-A Heterobicyclic amides as CD38 inhibitors 贝林格尔·英格海姆国际有限公司 2025-02-14 CN disclosed
CN-114645027-B Aminotransferase mutant from bacillus megatherium and application thereof 上海合全药物研发有限公司 2024-12-10 CN disclosed
CN-113166135-B Benzothiophene derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-10-25 CN disclosed
CN-114423753-B Heterobicyclic amides as CD38 inhibitors 里邦医疗公司 2024-09-17 CN disclosed
CN-116120213-B Synthesis method of trans-4- (tert-butoxycarbonylamino) cyclohexane carboxylic acid 重庆医药高等专科学校 2024-09-13 CN disclosed
US-5036104-A ENZYME INHIBITORS PFIZER INC. (US) 1991-07-30 US disclosed
US-5030654-A Glutaramide diuretic agents PFIZER INC. (US) 1991-07-09 US disclosed
US-4960792-A HYPOTENSIVE AGENTS PFIZER INC. (US) 1990-10-02 US disclosed
EP-0343911-A2 Cycloalkyl-substituted glutaramide diuretic agents Pfizer Limited (GB) 1989-11-29 EP disclosed
EP-0342850-A1 Enantiomeric glutaramide diuretic agents Pfizer Limited (GB) 1989-11-23 EP disclosed
EP-0274234-A2 Spiro-subsituted glutaramide diuretic agents Pfizer Limited (GB) 1988-07-13 EP disclosed
US-4148798-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1979-04-10 US disclosed
US-3975403-A Sulfur-containing ring compounds MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1976-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318484-A1 Inhibitors of JNK MAPK1, MAP3K6, MAP3K1 MAPT 1968/4885SMYD3 1902/4885ALDH1A1 4538/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B MAPT 4832/4885SMYD3 3059/4885ALDH1A1 877/4885
US-12459931-B2 Benzothiophene derivative regulator, preparation method therefor and use thereof GPER1, GABRQ, GPR39 MAPT 876/4885SMYD3 4553/4885ALDH1A1 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.